Group 1 - Tai Chi Group (600129) is facing significant challenges, including the freezing of bank accounts totaling over 62.92 million yuan due to contract disputes related to drug sales [1][2] - The company reported a 71.94% year-on-year decline in net profit for the first half of the year, attributed to policy impacts and ongoing inventory digestion of certain products [1][5] - Tai Chi Group has initiated the sale of idle properties, with a total listing price exceeding 64 million yuan, aiming to reduce operational costs and enhance sustainable business capabilities [1][4] Group 2 - The frozen accounts represent 1.73% of the company's latest audited net assets and 7.75% of its cash holdings, although the company claims this has not significantly impacted its operations [4] - Southwest Pharmaceutical Co., a subsidiary of Tai Chi Group, is involved in multiple legal disputes, including a 42.92 million yuan dispute with Tibet Huiye Pharmaceutical Technology Co. and a 20 million yuan dispute with Hangzhou Yueming Pharmaceutical Technology Co. [2][3] - The company has adjusted its 2024 profit forecast, projecting a 96.76% decline in net profit due to high inventory levels and previous years' performance [3][5] Group 3 - Tai Chi Group's revenue for the first half of the year was 5.658 billion yuan, down 27.63% year-on-year, with a projected revenue decline of 20.72% for 2024 [5][6] - The company has experienced a continuous decline in net profit over recent years, with the lowest profit level in nearly a decade expected for 2024 [5][7] - The company aims to achieve 50 billion yuan in revenue by 2025, but current performance indicates a significant gap from this target [7]